KIR genotype is associated with progression-free and overall survival following autologous stem cell transplantation for multiple myeloma

被引：0
|
作者：
Gabriel, I. [1 ]
Sargent, R. [1 ]
De Lavallade, H. [1 ]
Szydlo, R. [1 ]
Apperley, J. [1 ]
Khoder, A. [1 ]
Alsuliman, A. [1 ]
Marin, D. [1 ]
Foroni, L. [1 ]
Davis, J. [1 ]
Giles, C. [1 ]
Kanfer, E. [1 ]
Rahemtulla, A. [1 ]
Rezvani, K. [1 ]
机构：
[1] Imperial Coll NHS Trust, London, England
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S148 / S149
页数：2
相关论文
共 50 条
  • [31] XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant
    Persaud, Avinash K.
    Li, Junan
    Johnson, Jasmine A.
    Seligson, Nathan
    Sborov, Douglas W.
    Duah, Ernest
    Cho, Yu Kyoung
    Wang, Danxin
    Phelps, Mitch A.
    Hofmeister, Craig C.
    Poi, Ming J.
    [J]. MOLECULAR CARCINOGENESIS, 2019, 58 (12) : 2327 - 2339
  • [32] Induction Response Seems to Be A Prognostic Factor For Progression-Free Survival After Autologous Stem Cell Transplantation in Patients with Mutiple Myeloma
    Zapata Bautista, Rocio
    Velarde Lopez de Ayala, Pilar
    Palma Vallellano, Antonio J.
    [J]. BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 288 - 289
  • [33] Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint
    Rosenberg, Aaron Seth
    Facon, Thierry
    Abouzaid, Safiya
    Srinivasan, Shankar
    Chung, Weiyuan
    Parikh, Kejal
    Tuscano, Joseph
    [J]. BLOOD, 2017, 130
  • [34] Maintenance lenalidomide therapy following upfront autologous stem cell transplantation does not impact progression-free survival 2
    Luan, Danny
    Christos, Paul
    Guarneri, Danielle
    Van Besien, Koen
    Niesvizky, Ruben
    Rosenbaum, Cara
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E295 - E296
  • [35] Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
    Johnson, David C.
    Gregory, Walter M.
    Dickens, Nicholas J.
    Walker, Brian A.
    Szubert, Alex J.
    Davies, Faith E.
    Durie, Brian G. M.
    Van Ness, Brian G.
    Morgan, Gareth J.
    [J]. BLOOD, 2009, 114 (22) : 177 - 177
  • [36] Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma
    C Dumontet
    N Ketterer
    D Espinouse
    EM Neidhardt
    I Moullet
    C Thieblemont
    G Salles
    B Coiffier
    [J]. Bone Marrow Transplantation, 1998, 21 : 1037 - 1041
  • [37] Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma
    Dumontet, C
    Ketterer, N
    Espinouse, D
    Neidhardt, EM
    Moullet, I
    Thieblemont, C
    Salles, G
    Coiffier, B
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (10) : 1037 - 1041
  • [38] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [39] Soluble MICA as a prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, V.
    Schuett, P.
    Brandhorst, D.
    Opalka, B.
    Nowrousian, M. R.
    Moritz, T.
    Grosse-Wilde, H.
    [J]. TISSUE ANTIGENS, 2007, 69 (05): : 390 - 390
  • [40] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
12345